Key result
The interventional diagnostic procedure, comprising guidewire and pharmacological reactivity tests, aids in differentiating endotypes of coronary vasomotion syndromes in patients with ANOCA.
Why the study?
Approximately 40% of patients undergoing invasive coronary angiography for angina have ANOCA, and guidance was needed on preparing and administering interventional diagnostic procedures to identify underlying coronary vasomotion endotypes.
This practical guide outlines the preparation and administration of the interventional diagnostic procedure (IDP) for assessing coronary vascular function in patients with ANOCA to support personalized medicine.
Answers are grounded in this paper and cite their sources.
Distinct ANOCA endotypes support function testing in angina; leaves open endotype-specific therapies for prospective trials.
Approximately 40% of patients undergoing invasive coronary angiography for investigation of angina are found to have no obstructive coronary artery disease (ANOCA). Abnormal coronary function underlies coronary vasomotion syndromes including coronary endothelial dysfunction, microvascular angina, vasospastic angina, post-PCI angina and myocardial infarction with no obstructive coronary arteries (MINOCA). Each of these endotypes are distinct subgroups, characterized by specific disease mechanisms. Diagnostic criteria and linked therapy for these conditions are now established by expert consensus and clinical guidelines. Coronary function tests are performed as an adjunctive interventional diagnostic procedure (IDP) in appropriately selected patients during coronary angiography. This aids differentiation of patients according to endotype. The IDP includes two distinct components: a diagnostic guidewire test and a pharmacological coronary reactivity test. The tests last approximately 5 minutes for the former and 10-15 minutes for the latter. Patient safety and staff education are key. The diagnostic guidewire test measures parameters of coronary flow limitation (fractional flow reserve [FFR], coronary flow reserve [CFR], microvascular resistance [index of microvascular resistance (IMR)], basal resistance index, and vasodilator function [CFR, resistive reserve ratio (RRR)]). The pharmacological coronary reactivity test measures the vasodilator potential and propensity to vasospasm of both the main coronary arteries and the micro-vessels. It involves intra-coronary infusion of acetylcholine and glyceryl trinitrate (GTN). Acetylcholine is not licensed for parenteral use and is therefore prescribed on a named-patient basis. Vasodilatation is the normal, expected response to infusion of physiological concentrations of acetylcholine. Vascular spasm represents an abnormal response, which supports the diagnosis of vasospastic angina. The purpose of this practical guide is to provide information on the preparation and administration of the IDP in clinical practice. It discusses some key preparation and safety considerations, as well as tips for procedural success. The IDP supports stratified medicine for a personalized approach to health and wellbeing.
No takes yet. Share an insight, caveat, or question.
Ang et al. (2022) conducted a review in Angina with no obstructive coronary artery disease (ANOCA). Interventional diagnostic procedure (IDP) was evaluated. The interventional diagnostic procedure, comprising guidewire and pharmacological reactivity tests, aids in differentiating endotypes of coronary vasomotion syndromes in patients with ANOCA.
Synapse has enriched 10 related papers. Consider them for comparative context: